CARDIFF ONCOLOGY, INC. Proceeds from Long-term Capital Lease Obligations
CARDIFF ONCOLOGY, INC. (CRDF) reported Proceeds from Long-term Capital Lease Obligations of $0 for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermCapitalLeaseObligations · last filed 2015-11-09
- CARDIFF ONCOLOGY, INC. proceeds from long-term capital lease obligations for the quarter ending 2014-12-31 was -$15.45M.
- CARDIFF ONCOLOGY, INC. proceeds from long-term capital lease obligations for the quarter ending 2014-09-30 was $515.96K, a 156.96% increase year-over-year.
- CARDIFF ONCOLOGY, INC. proceeds from long-term capital lease obligations for the quarter ending 2014-06-30 was $14.47M.
- CARDIFF ONCOLOGY, INC. proceeds from long-term capital lease obligations for the quarter ending 2014-03-31 was -$48.64K.
- CARDIFF ONCOLOGY, INC. proceeds from long-term capital lease obligations for fiscal 2014 was -$515.96K, a 200.00% decline from fiscal 2013.
- CARDIFF ONCOLOGY, INC. proceeds from long-term capital lease obligations for fiscal 2013 was $515.96K.
| Period end | Proceeds from Long-term Capital Lease Obligations 3 month | Proceeds from Long-term Capital Lease Obligations 6 month | Proceeds from Long-term Capital Lease Obligations 9 month | Proceeds from Long-term Capital Lease Obligations 9 month as first filed | Proceeds from Long-term Capital Lease Obligations 12 month | Proceeds from Long-term Capital Lease Obligations 167 month | Proceeds from Long-term Capital Lease Obligations 170 month | Proceeds from Long-term Capital Lease Obligations 173 month | Proceeds from Long-term Capital Lease Obligations 176 month |
|---|---|---|---|---|---|---|---|---|---|
| 2015-09-30 | $0.00 10-Q · filed 2015-11-09 | ||||||||
| 2014-12-31 | -$15.45M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$14.94M derived: sum of 2 quarters · filed 2015-11-09 | -$467.33K derived: sum of 3 quarters · filed 2015-11-09 | -$515.96K 10-K · filed 2015-03-12 | |||||
| 2014-09-30 | $515.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $14.99M derived: sum of 2 quarters · filed 2015-11-09 | $14.94M 10-Q · filed 2015-11-09 | -$515.96K 10-Q · filed 2014-11-06 | $14.94M derived: sum of 4 quarters · filed 2015-11-09 | ||||
| 2014-06-30 | $14.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $14.42M 10-Q · filed 2015-08-10 | $14.42M derived: sum of 3 quarters · filed 2015-08-10 | $14.62M derived: sum of 4 quarters · filed 2015-08-10 | |||||
| 2014-03-31 | -$48.64K 10-Q · filed 2015-05-05 | -$48.64K derived: sum of 2 quarters · filed 2015-05-05 | $152.16K derived: sum of 3 quarters · filed 2015-05-05 | $467.33K 10-Q · filed 2014-05-12 | |||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $200.80K derived: sum of 2 quarters · filed 2015-03-12 | $515.96K 10-K · filed 2015-03-12 | $515.96K 10-K · filed 2014-03-17 | |||||
| 2013-09-30 | $200.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $515.96K 10-Q · filed 2014-11-06 | $515.96K 10-Q · filed 2013-11-14 | ||||||
| 2013-06-30 | $315.17K 10-Q · filed 2014-08-07 | $315.17K 10-Q · filed 2013-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |